Compounds suited as nanocarriers for active agents and their use
The invention relates to a compound suited as entity carrier, having the general formula (I) wherein X is an amine-containing residue further defined herein. The invention further relates to the use of such compounds, a nanocarrier system, a kit comprising such compounds and methods for gene silencing and anti-cancer treatment.
1. A compound consisting of a linear or branched polyglycerol, wherein at least 50% of the free hydroxyl groups of the polyglycerol core are substituted by an amine-containing group, said amine-containing group having a general formula selected from the group consisting of:
wherein:
R 1 and R 2 are each independently selected from the group consisting of hydrogen, R 3 , and a linear or branched C 1 -C 10 -alkyl, which may be substituted and/or interrupted by one or more oxygen, sulphur and/or nitrogen atoms, provided that at least one of R 1 and R 2 is not hydrogen;
R 3 is selected from the group consisting of 4-aminobutyl, 4-(3-aminopropylamino)butyl, 3-(4-aminobutylamino)propyl, 3-(3-aminopropylamino)propyl, 3-(4-(3-aminopropylamino)butylamino)propyl, and
R 4 is selected from the group consisting of hydrogen and a C 1 -C 4 -alkyl, which may be substituted and/or interrupted by one or more oxygen, sulphur and/or nitrogen atoms; and
n is an integer in a range of from 1 to 100.
2. The compound of claim 1 , wherein R 1 is selected from the group consisting of hydrogen and said R 3 .
3. The compound of claim 1 , wherein R 2 is said R 3 , and R 1 and R 4 are each hydrogen, such that said amine-containing group has a general formula selected from the group consisting of:
4. The compound of claim 1 , wherein at least 90% of the free hydroxyl groups of the polyglycerol core are substituted by said amine-containing group.
5. The compound of claim 1 , wherein n is in a range of from 1 to 10.
6. The compound of claim 1 , wherein R 1 and R 2 are not simultaneously ethyl.
7. A nanocarrier system comprising the compound of claim 1 and at least one entity bound to said compound in a covalent, ionic or complexed manner, wherein said entity is selected from the group comprising nucleotides, nucleosides, linear or circular single or double stranded oligonucleotides, oligomeric molecules comprising at least one nucleoside, small pharmacologically active molecules having a molecular mass of not more than 800 g/mol, amino acids, peptides, and metal ions.
8. The nanocarrier system of claim 7 , wherein said entity is an oligonucleotide.
9. The nanocarrier system of claim 7 , wherein said entity is a ribonucleic oligonucleotide.
10. The nanocarrier system of claim 9 , wherein said ribonucleic oligonucleotide has a length of 8 to 50 bases.
11. The nanocarrier system of claim 7 , wherein R 2 is said R 3 , and R 1 and R 4 are each hydrogen, such that said amine-containing group has a general formula selected from the group consisting of:
12. The nanocarrier system of claim 7 , wherein at least 90% of the free hydroxyl groups of the polyglycerol core are substituted by said amine-containing group.
13. The nanocarrier system of claim 7 , wherein n is in a range of from 1 to 10.
14. A method of transporting an entity into at least one human or animal cell, the method comprising contacting the cell with the nanocarrier system of claim 7 .
15. The method of claim 14 , being for silencing a gene in vitro, ex vivo, in situ or in vivo, wherein said entity is a ribonucleic oligonucleotide.
16. The method of claim 15 , wherein said gene to be silenced is a tumor related gene.
17. A kit for performing a transfection reaction, the kit comprising the nanocarrier system of claim 7 in any suited formulation.
18. A method of treating cancer in a human or animal subject in need thereof, the method comprising administering the nanocarrier system of claim 7 to the subject, thereby treating the cancer.
19. The method of claim 18 , being performed as a combination treatment which further comprises administering a known anti-cancer or anti-angiogenic drug.
20. A nanocarrier system, comprising:
a) a nanocarrier compound consisting of a linear or branched polyglycerol, wherein at least 50% of the free hydroxyl groups of the polyglycerol core are substituted by an amine-containing group, said amine-containing group having a general formula selected from the group consisting of:
wherein:
R 1 and R 2 are each independently selected from the group consisting of hydrogen, R 3 , and a linear or branched C 1 -C 10 -alkyl, which may be substituted and/or interrupted by one or more oxygen, sulphur and/or nitrogen atoms;
R 3 is selected from the group consisting of 4-aminobutyl, 4-(3-aminopropylamino)butyl, 3-(4-aminobutylamino)propyl, 3-(3-aminopropylamino)propyl, 3-(4-(3-aminopropylamino)butylamino)propyl, and
R 4 is selected from the group consisting of hydrogen and a C 1 -C 4 -alkyl, which may be substituted and/or interrupted by one or more oxygen, sulphur and/or nitrogen atoms; and
n is an integer in a range of from 1 to 100, and
b) at least one entity bound to said nanocarrier compound in a covalent, ionic or complexed manner, said entity being selected from the group consisting of nucleotides, nucleosides, oligonucleotides, oligomeric molecules comprising at least one nucleoside, small pharmacologically active molecules having a molecular mass of not more than 800 g/mol, amino acids and peptides.
21. The nanocarrier system of claim 20 , wherein said entity does not comprise a double stranded circular and covalently closed nucleic acid having a length of more than 1000 bases or base pairs.
22. The nanocarrier system of claim 20 , wherein said entity is an oligonucleotide.
23. The nanocarrier system of claim 20 , wherein said entity is a ribonucleic oligonucleotide.
24. The nanocarrier system of claim 23 , wherein said ribonucleic oligonucleotide has a length of 8 to 50 bases.
25. The nanocarrier system of claim 20 , wherein R 1 and R 2 are each hydrogen.
26. The nanocarrier system of claim 20 , wherein at least 90% of the free hydroxyl groups of the polyglycerol core are substituted by said amine-containing group.
27. The nanocarrier system of claim 20 , wherein said nanocarrier compound comprises at least one amine-containing group having the general formula:
28. A method of transporting an entity into at least one human or animal cell, the method comprising contacting the cell with the nanocarrier system of claim 20 .
29. The method of claim 28 , being for silencing a gene in vitro, ex vivo, in situ or in vivo, wherein said entity is a ribonucleic oligonucleotide.
30. The method of claim 29 , wherein said gene to be silenced is a tumor related gene.
31. A kit for performing a transfection reaction, the kit comprising the nanocarrier system of claim 20 in any suited formulation.
32. A method of treating cancer in a human or animal subject in need thereof, the method comprising administering the nanocarrier system of claim 20 to the subject, thereby treating the cancer.
33. The method of claim 32 , being performed as a combination treatment which further comprises administering a known anti-cancer or anti-angiogenic drug.